The Technical Analyst
Legend Biotech Corp [LEGN]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Legend Biotech Corp Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
-1.97% $46.19
America/New_York / 19 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 8 402.47 mill |
| EPS: | -2.94 |
| P/E: | -15.71 |
| Earnings Date: | May 13, 2024 |
| SharesOutstanding: | 181.91 mill |
| Avg Daily Volume: | 1.004 mill |
| RATING 2024-04-19 |
|---|
| B- |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Buy | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | n/a | |||||
| Debt | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -15.71 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -2.67x |
| Company: PE -15.71 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 43.36 - 49.02 ( +/- 6.12%) |
| ATR Model: 14 days |
Forecast:
16:00 - $46.15
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $46.15
Forecast 2: 16:00 - $46.15
Forecast 3: 16:00 - $46.15
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $46.19 (-1.97% ) |
| Volume | 1.231 mill |
| Avg. Vol. | 1.004 mill |
| % of Avg. Vol | 122.68 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For LEGN
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $58.33 | N/A | Active |
|---|
LEGN
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM), as well as a comparison of the treatment with standard triplet therapy in revlimid-refractory multiple myeloma. The company also has a portfolio of earlier-stage autologous product candidates, which are in Phase I clinical trials for the treatment of gastric cancer and T cell lymphoma. In addition, it is developing CAR-T product candidates targeting CD20/CD22/CD19 for the treatment of non-hodgkins lymphoma, diffuse large B-cell lymphoma, and acute lymphoblastic leukemia. Further, the company has product candidates in early preclinical and clinical development for the treatment of solid tumors as well as infectious diseases. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. Legend Biotech Corporation was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.
Latest Press Releases
2024-04-11 08:00:00 - Press Release
Legend Biotech To Host Investor Conference Call On First Quarter 2024 Results
Somerset, n.j.--(business wire)--legend biotech corporation (nasdaq: legn) (legend biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am et on monday, may 13, 2024, to review first-quarter 2024 results. during the webcast and conference call, senior leaders will provide an overview of legend biotech's performance for the quarter. investors and other interested parties may join the live audio webcast of the call via this weblink. a replay version of the.
2024-04-05 23:30:00 - Press Release
Legend Biotech's Carvykti® (ciltacabtagene Autoleucel) Becomes The First And Only Bcma-targeted Car-t Cell Therapy Approved By The Fda For Second-line Treatment Of Multiple Myeloma
Somerset, n.j.--(business wire)--legend biotech corporation (nasdaq: legn) (legend biotech), a global leader in cell therapy, announced today the u.s. food and drug administration (fda) has approved carvykti® (ciltacabtagene autoleucel; cilta-cel) for the treatment of patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor (pi), and an immunomodulatory agent (imid), and are refractory to lenalidomide.1 carvykti.
2024-03-19 08:30:00 - Press Release
Legend Biotech Announces Publication Of Inaugural Environmental, Social And Governance (esg) Report
Somerset, n.j.--(business wire)--legend biotech corporation (nasdaq: legn) (legend biotech), a global leader in cell therapy, today released its inaugural environmental, social & governance (esg) report. the inaugural report provides an overview of legend biotech's esg program and reporting in alignment with the sustainable accounting standards board (“sasb”) biotechnology and pharmaceutical sector standards, the company's esg data collection and disclosure roadmap, and future growth areas.
2024-03-15 15:15:00 - Press Release
Carvykti® (ciltacabtagene Autoleucel) Receives Recommendation From The U.s. Fda Oncologic Drugs Advisory Committee For Earlier Treatment Of Patients With Relapsed/refractory Multiple Myeloma
Somerset, n.j.--(business wire)--legend biotech corporation (nasdaq: legn) (legend biotech), a global leader in cell therapy, announced today that the u.s. food and drug administration (fda) oncologic drugs advisory committee (odac) recommended carvykti® (ciltacabtagene autoleucel, cilta-cel) for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy including a proteasome inhibitor (pi) and an immunomodulatory agent (im.
2024-03-11 07:00:00 - Press Release
Legend Biotech Reports Fourth Quarter And Full Year 2023 Results And Recent Highlights
Somerset, n.j.--(business wire)--legend biotech corporation (nasdaq: legn) (legend biotech), a global leader in cell therapy, today reported its fourth quarter and full year 2023 unaudited financial results and key corporate highlights. “with worldwide sales of half a billion dollars in its first full year of commercialization, our rapid, successful launch of carvykti® reinforces its position as a leading car-t therapy for patients with relapsed and refractory multiple myeloma,” said ying huang.
Latest News
2024-04-08 09:50:32 - Zacks Investment Research
Why Legend Biotech (LEGN) Stock Might be a Great Pick
Legend Biotech (LEGN) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
2024-03-11 12:09:08 - Seeking Alpha
Legend Biotech Corporation (LEGN) Q4 2023 Earnings Call Transcript
Legend Biotech Corporation (NASDAQ:LEGN ) Q4 2023 Earnings Conference March 11, 2024 8:00 AM ET Company Participants Jessie Yeung - Head of Investor Relations and Public Relations Ying Huang - Chief Executive Officer Lori Macomber - Chief Financial Officer Guowei Fang - Chief Scientific Officer and Head of Business Development Steve Gavel - Senior Vice President, Commercial Development, US and Europe Conference Call Participants Jessica Fye - J.P. Morgan Jonathan Miller - Evercore ISI Ziyi Chen - Goldman Sachs Dave Windley - Jefferies Leonid Timashev - RBC Capital Markets Vikram Purohit - Morgan Stanley Kostas Biliouris - BMO Capital Markets Ashwani Verma - UBS Edward Tenthoff - Piper Sandler Justin Zelin - BTIG Mitchell Kapoor - H...
2024-03-11 08:31:01 - Finbold
Next-gen leaders: The biotech stock set to soar on groundbreaking innovation
The biotech industry is evolving rapidly, with 2024 poised to be a year of significant advancements and opportunities. Amidst an uncertain macroeconomic environment, the biotech sector is gaining momentum, fueled by groundbreaking innovations and favorable market conditions.
2024-03-08 08:36:05 - Zacks Investment Research
5 Biotechnology Stocks to Buy for a Stable Portfolio in 2024
We have narrowed our search to five biotech stocks with strong potential for 2024. These are MOR, LEGN, ASND, EXEL and EXAS.
2024-01-23 09:10:45 - Zacks Investment Research
FDA Demands "Boxed Warning" to CAR T-Cell Therapy Labels
The FDA directs companies like NVS, BMY, GILD and others to add "boxed warning" to the labels of their CAR T-cell immunotherapies after it identified adverse events.
2023-11-29 09:46:17 - Zacks Investment Research
CAR T-Cell Therapies Under FDA Watch on Reports of Malignancies
The FDA has undertaken an investigation of T-cell malignancies in patients undergoing CAR T-cell therapy treatment. Therapies from NVS, BMY and GILD are under the spotlight.
2023-11-20 09:46:24 - Zacks Investment Research
5 Biotechnology Stocks to Buy for a Stable Portfolio in 2024
We have narrowed our search to five biotech stocks with strong potential for 2024. These are: LEGN, BGNE, GILD, EXAS, SRPT.
2023-11-20 07:18:53 - Proactive Investors
Legend Biotech highlights Novartis deal worth up to $1.11BN alongside 3Q results
Legend Biotech Corporation (NASDAQ:LEGN) highlighted an exclusive license agreement struck with Novartis AG (ADR) (NYSE:NVS) worth up to $1.11 billion as it released third-quarter results. Under the agreement, its Legend Biotech Ireland subsidiary has granted Novartis the rights to develop, manufacture and commercialize its CAR-T cell therapy candidate LB2102 and other potential chimeric antigen receptor T-cell therapies selectively targeting Delta-like ligand 3 (DLL3).
2023-11-14 12:02:12 - Zacks Investment Research
Should You Buy Legend Biotech (LEGN) Ahead of Earnings?
Legend Biotech (LEGN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
2023-11-09 08:16:09 - Zacks Investment Research
4 Biotech Stocks Likely to Outpace Q3 Earnings Estimates
Let us look at a few biotech companies, ACLX, LEGN, GRCL and EYEN, which are poised to beat third-quarter earnings estimates.